What is the latest research on access to treatments for the emerging corona virus "Covid-19" to be taken by mouth?

How does it work?

Do we expect to get a medicine for this disease soon?

We start with the American company Pfizer, which is developing a specially designed pill to stop the Corona virus - its scientific name is "SARS-CoV-2" - according to a report in the Daily Telegraph.

Pfizer will begin human trials, and if successful, a home treatment for Covid-19 will likely be available later this year.

The molecule being tested is an antiviral labeled "PF 07321332" (PF 07321332), classified as a "protease inhibitor", and was designed to attack the "backbone" of the coronavirus and prevent it from multiplying in the nose, throat and lungs.

Protease inhibitor drugs work by affecting the virus's ability to make new viruses inside cells, by blocking an enzyme known as a protease that breaks down virus proteins that are used to produce new viruses.

When proteases are inhibited, the virus cannot break down the proteins to produce new viruses, and as a result, it cannot reproduce and stops its spread.

 The drug was developed from scratch during the current pandemic, David Owen, director of medicinal chemistry at Pfizer, said at a special medical chemistry department last month.

The first 7 milligrams of the compound were made in late July, and by late October they had made 100 grams of the drug, and after just two weeks, they had more than a kilogram.

"We have designed BF 07321332 as a potential oral treatment that can be prescribed at the first sign of infection, without the need for patients to be hospitalized or in critical care," said Pfizer's chief scientific officer, Mikael Dolstein, in an official statement issued last month.

The first human experiences

The telegraph obtained copies of the documents given to the participants now entering the first human experiences.

The documents, which were officially approved on February 8th, say, “So far, the drug has not been administered to humans .. The safety of the study drug has been studied in animals. In these animal studies, there are no significant safety or safety risks. For concern, the study drug did not cause side effects at any of the dosage levels that would be used in the clinical studies.

The trial is divided into 3 phases, and will last for 145 days, with an additional 28 days added for examination and dosing.

Molnopiravir

We are moving to Merck, the American company, which is working with Ridgeback Biotherapeutics on the drug Molnupiravir, an antiviral therapeutic oral treatment, to treat Corona.

The data indicate that molnopiravir prevents the virus from multiplying, according to a statement issued by the company.

The drug is currently in the study phase in humans.

"We are delighted that molnopiravir continues to emerge as a potential treatment for outpatients with COVID-19," said Wendy Holman, CEO of Ridgback Biotherapy.

He added that the data provides convincing evidence of antiviral activity in Molnopiravir.